Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)

Fecal Incontinence Clinical Trial

— SoFI  

Official title:

A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01647906
• Other study ID #: CL SLP001
• Status: Completed
• Start date: May 31, 2012
• Est. completion date: September 15, 2018

Study information

• Verified date: November 2019
• Source: Bausch Health Americas, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this observational study is to evaluate the safety and effectiveness of the Solesta Injectable Bulking Agent in the treatment of fecal incontinence through 3 years in a real world setting.

Description:

This observational study is to evaluate the safety and effectiveness of the Solesta Injectable Bulking Agent in the treatment of fecal incontinence through 3 years in a real world setting.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 277
• Est. completion date: September 15, 2018
• Est. primary completion date: September 15, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: A patient will be eligible for study participation if he/she meets the following criteria:

• Able to fluently speak and understand the language in which the study is being conducted and able to provide meaningful written informed consent for the study.

• Have FI, have failed conservative therapy (e.g., diet, fiber therapy, medications that treat diarrhea), and are scheduled to receive Solesta treatment.

• Females must be of non-childbearing potential; or females of childbearing (reproductive) potential must agree to use an acceptable method of contraception for at least the first 6 months of study participation and have a negative urine pregnancy test at Visit 1 (Screening/Baseline) and immediately prior to receiving initial Solesta treatment. Women who are surgically sterile or those who are post menopausal for at least 2 years prior to entering the study are not considered to be of childbearing potential.

• Willing to return to the study facility for the post treatment evaluation.

Exclusion Criteria: A patient will be excluded from the study if he/she meets any of the following criteria:

• Is currently pregnant, breastfeeding, or is planning to become pregnant over the course of the study.

• Has an active inflammatory bowel disease.

• Has an immunodeficiency disorder or ongoing immunosuppressive therapy.

• Has received previous radiation treatment to the pelvic area.

• Has significant mucosal or full thickness rectal prolapse.

• Has active anorectal conditions including: abscess, fissures, sepsis, bleeding, proctitis, or other infections.

• Has anorectal atresia, tumors, stenosis or malformation.

• Has a rectocele.

• Has rectal varices.

• Has presence of existing implant including Solesta, artificial bowel sphincter, or sacral nerve stimulator (activated or inactivated).

• Has an allergy to hyaluronic acid (HA) based products.

• Has an anastomosis to the rectum or anus within 10 cm of the dentate line.

• Has an unstable condition (e.g., psychiatric disorder, a recent history of substance abuse) or otherwise thought to be unreliable or incapable of complying with the requirements of the post-approval study protocol.

• Has any disorder that, in the opinion of the Investigator, might interfere with the conduct of the study.

• Has undergone sphincteroplasty, graciloplasty, or other surgical interventions (without the use of an implanted device) for treatment of fecal incontinence within 12 months of enrollment.

• Has any bleeding disorder.

Related Conditions & MeSH terms

• Fecal Incontinence

Locations

Country	Name	City	State
United States	Colon and Rectal Research Foundation	Allentown	Pennsylvania
United States	Emory University	Atlanta	Georgia
United States	Georgia Regents Research Institute	Augusta	Georgia
United States	University of Vermont Medical Center	Burlington	Vermont
United States	Cleveland Clinic Foundation Digestive Disease Institute	Cleveland	Ohio
United States	The Iowa Clinic	Des Moines	Iowa
United States	North Shore Long Island Jewish Health Systems	Huntington	New York
United States	Colon and Rectal Medical Services	Los Angeles	California
United States	Colon and Rectal Surgery Associates, Ltd.	Minneapolis	Minnesota
United States	Mount Sinai Medical Center	New York	New York
United States	NYU Langone Medical Center	New York	New York
United States	University of Oklahoma Health Sciences Center	Oklahoma City	Oklahoma
United States	Colon and Rectal Surgery, LLC	Omaha	Nebraska
United States	University of California Irvine Medical Center	Orange	California
United States	Drexel University College of Medicine	Philadelphia	Pennsylvania
United States	Galliano Private Practice	Port Charlotte	Florida
United States	Mayo Clinic	Scottsdale	Arizona
United States	USF Health	Tampa	Florida
United States	North Pinellas Surgical Institute	Tarpon Springs	Florida
United States	Cleveland Clinic Florida Health	Weston	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Bausch Health Americas, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Freedom from fecal incontinence reintervention	The primary effectiveness endpoint is freedom from Fecal Incontinence Reintervention. Patients will be evaluated at 3, 6, 12, 24, and 36 months after the last Solesta treatment for the occurrence (or lack of occurrence) of Fecal Incontinence Reintervention. Fecal Incontinence Reintervention includes Fecal Incontinence treatment of sphincteroplasty, implantation of artificial bowel sphincter, retreatment with Solesta, graciloplasty, sacral nerve stimulation (SNS) or other surgical interventions that occur more than 3 months after the last primary Solesta treatment.	Through 36 months after the last Solesta treatment
Secondary	Fecal Incontinence Quality of Life (FIQL)	The effectiveness endpoint of Fecal Incontinence Quality of Life using the Rockwood instrument will be assessed at baseline, 3, 6, 12, and 36 months after last Solesta treatment. Patients will fill out a questionnaire at screening visit and at follow up visits. The Fecal Incontinence Quality of Life instrument is a questionnaire completed by patients that assesses the impact of quality of life as it relates to Lifestyle, Coping/Behavior, Depression/Self perception and Embarrassment. The FIQL instrument consists of a total of 29 questions.	Assessed at baseline, 3, 6, 12, and 36 months after last Solesta treatment.
Secondary	Cleveland Clinic Florida Fecal Incontinence Score (CCFIS)	The effectiveness endpoint of CCFIS will be assessed at baseline, 6, 12, and 36 months after last Solesta treatment. The investigator will calculate the CCFIS based on a patient interview. The CCFIS is a summed score of 5 individual parameters (i.e., frequency of incontinence to gas, liquid, solid, of need to wear pad, and of lifestyle changes).	Assessed at baseline,3, 6, 12, and 36 months after last Solesta treatment
Secondary	Global Perceived Effect Score	The effectiveness endpoint of Global Perceived Effect Score will be assessed at 6, 12 and 36 months after last Solesta treatment. Global perceived effect is a subjective score and reflects the patient perception of their degree of FI after treatment compared to the period before treatment and ranges from 1-7 points.	Assessed at 6, 12 and 36 months after last Solesta treatment
Secondary	Time to Fecal Incontinence Reintervention	For patients who undergo Fecal Incontinence Reintervention the effectiveness endpoint of Time to Fecal Incontinence Reintervention will be measured from the date of last treatment with Solesta to the date of first Fecal Incontinence Reintervention. Fecal incontinence reinterventions will include any of the following FI treatments: sphincteroplasty, implantation of artificial bowel sphincter, retreatment with Solesta, graciloplasty, SNS or other surgical interventions.	Assessed from 6 to 36 months after last Solesta treatment
Secondary	Anatomic stability of the Solesta	Assess the relative anatomic stability of the Solesta Injectable Bulking Agent in a subpopulation of patients enrolled at 3-4 sites as assessed by transrectal ultrasound. Solesta will be assessed by comparing anatomical positioning of the Solesta implant, as determined by transrectal ultrasound at Visit 3a (for patients who did not receive a second Solesta treatment) or Visit 3b (for patients who received a second Solesta treatment at Visit 3a) to positioning at 6 and 36 months after the last Solesta treatment.	Assessed at time of Solesta treatment and again at 6 and 36 months after the last Solesta treatment.
Secondary	Occurrence of any peri-injection device related infectious adverse events.	A secondary safety endpoint will be the occurrence of peri-injection device related infectious Adverse Events for patients treated with or without prophylactic antibiotics (as decided by treating physician) prior to injection.	Assessed from time of injection up to 2 weeks after Solesta treatment